Step-down therapy to preserve spine bone density after long-term denosumab
Official title: Step-down Therapy After Long-term Osteoporosis Treatment: A Randomized Trial
Run by National Taiwan University Hospital · NCT07281586 · Data updated 2026-11-12
This test sees if switching to half-dose denosumab every six months plus a zoledronic acid infusion better preserves lumbar spine bone density in men and postmenopausal women aged 50–85 who have used denosumab for at least three years.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 50 Years to 85 Years |
| Sex | All |
| Enrollment | 44 (estimated) |
| Sponsor | National Taiwan University Hospital Academic / other |
| Drugs / interventions | denosumab |
| Locations | 1 site (Douliu, Taiwan) |
| Status | Recruiting |
| Started | January 1, 2026 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2028 |
| Registry record updated | December 15, 2025 |
| Trial ID | NCT07281586 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Postmenopausal women and men aged 50–85 with osteoporosis or osteopenia-related fractures who have received continuous denosumab for at least three years without dosing gaps over nine months are the intended participants.
✕Probably not a fit
Patients with secondary metabolic bone disease, active or prior malignancy, ongoing systemic glucocorticoid use, current bone-active medications, significant renal impairment (eGFR <50 mL/min/1.73 m²), hypocalcemia, or known hypersensitivity to zoledronic acid are ineligible and unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This open-label Phase 4 trial randomizes 44 participants, stratified by prior denosumab duration (<4 years vs ≥4 years), to test a de-escalation strategy of half-dose denosumab (30 mg every six months) combined with sequential zoledronic acid versus standard sequential zoledronic acid. Enrollment includes postmenopausal women and men aged 50–85 with osteoporosis or osteopenia-related fractures who have received continuous denosumab for ≥3 years. The primary focus is preservation of lumbar spine bone mineral density, with particular attention to the first year after changing therapy when rebound bone loss is greatest. The trial is single-center and open-label, with bone density and safety monitoring over the follow-up period.
Why it matters
Potential benefit: If successful, this approach could reduce the rapid bone loss and short-term fracture risk that commonly follow stopping long-term denosumab.
How similar studies have gone: Sequential bisphosphonate transitions after denosumab have shown mixed results in preventing rebound bone loss, and the half-dose denosumab de-escalation combined with zoledronic acid is a relatively new approach with limited prior evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Postmenopausal women aged ≥50 and ≤85 years with osteoporosis- or osteopenia-related fractures who have received denosumab (Prolia) continuously for at least 3 years, with no dosing interval exceeding 9 months; and men aged ≥50 and ≤85 years with osteoporosis- or osteopenia-related fractures who have received continuous denosumab (Prolia) therapy for at least 3 years, with dosing intervals not exceeding 9 months. Exclusion Criteria: * Secondary osteoporosis Metabolic bone diseases Active or prior malignancy Ongoing systemic glucocorticoid therapy Current use of hormone replacement therapy Use of any medications that affect bone metabolism Estimated glomerular filtration rate (eGFR) \< 50 mL/min/1.73 m² Known hypersensitivity to zoledronic acid Hypocalcemia Any other contraindications to zoledronic acid use
Where it's running
-
National Taiwan University Hospital Yunlin Branch
Douliu, Taiwan, Taiwan Recruiting
Study contacts
- Study coordinator: Shau-Huai Fu, PhD
- Email: b90401045@gmail.com
- Phone: +886972655734
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Role of LH and hCG in adults being evaluated for endocrine disorders
This study looks at whether levels of luteinizing hormone (LH) and hCG in adults undergoing endocrine evaluation relate to their disease presence and outcomes.
-
Can a blood marker called lumican reveal hidden fragility in postmenopausal osteoporosis
This study tests whether serum lumican levels can help identify hidden fragility risk in postmenopausal women beyond what bone density shows.
-
Functional Muscle-Bone Incongruity Index: A look at muscle strength and bone health in adults
This observational study tests a composite FKUI score using handgrip strength and hip/spine bone density to see if it better reflects musculoskeletal health than each measure alone in adults undergoing routine DXA.
-
Vessel-X Bone Filling Container System for Vertebral Augmentation
A new minimally invasive vertebral augmentation approach tests the Vessel-X device to see if it safely improves pain and function in people with osteoporotic vertebral compression fractures.
-
Proximal Humerus Cortical Thickness in Post-Stroke Paresis
This study tests whether measurements of the outer bone thickness of the upper arm (the humerus) on the paretic side after a stroke reflect regional bone loss and how well they agree with standard bone density tests.
-
People with Osteoporosis: See if Walk-BEST Gait Program Helps You Walk Safer
This pilot study tests whether older adults with osteoporosis can use the Walk-BEST gait training with a wearable sensor to walk more safely and reduce fall risk.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.